|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 EUR | +5.93% |
|
+2.80% | -2.95% |
| 14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
| 11/03 | Abionyx: reduced net loss in 2023 | CF |
Cerenis Therapeutics announced the appointment of Richard Pasternak as new Chief Executive Officer, effective December 18, 2018. Richard Pasternak replaces Jean-Louis Dasseux, who is standing down from his executive duties but will retain his place on the Board of Directors. Richard Pasternak remains Chairman of the Board of Directors.
On the proposal of the new CEO, current CFO Cyrille Tupin has been appointed Deputy Chief Executive Officer by the Board of Directors.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.95% | 43.66M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
ABIONYX PHARMA 
